Table 3. Clinical Outcomes.
Outcome | Docetaxel N = 25 | Docetaxel and bevacizumab N = 24 |
---|---|---|
Surgical candidate | 19 (76%) | 19 (79%) |
Breast conserving surgery | 7 (37%) | 1 (5%) |
Modified radical mastectomy | 12 (63%) | 18 (95%) |
Inadequate disease response | 3 | 3 |
Disease progression on therapy | 3 | 1* |
Delayed wound healing post-surgery | 3 (16%) | 5 (26%) |
Plus one treatment related death